Home  |  Contact

UniProtKB/Swiss-Prot Q8IV16: Variant p.Thr108Arg

Glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1
Gene: GPIHBP1
Chromosomal location: 8q24.3
Variant information

Variant position:  108
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Threonine (T) to Arginine (R) at position 108 (T108R, p.Thr108Arg).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and polar (T) to large size and basic (R)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Involvement in disease:  Hyperlipoproteinemia 1D (HLPP1D) [MIM:615947]: An autosomal recessive disorder characterized by hyperlipoproteinemia, decreased plasma LPL levels in some patients, high plasma triglyceride levels, and refractory fasting chylomicronemia. {ECO:0000269|PubMed:19304573, ECO:0000269|PubMed:20026666, ECO:0000269|PubMed:21314738, ECO:0000269|PubMed:21816778, ECO:0000269|PubMed:22239554, ECO:0000269|PubMed:23831619, ECO:0000269|PubMed:25387803, ECO:0000269|PubMed:27578123}. Note=The disease is caused by mutations affecting the gene represented in this entry.
The name and a short description of the disease associated with the variant. For more information about the disease, the user can refer to OMIM, following the link provided after the disease acronym.

Variant description:  In HLPP1D; does not interact with LPL; promotes formation of dimers and oligomers reducing number of monomers.
Any additional useful information about the variant.



Sequence information

Variant position:  108
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  184
The length of the canonical sequence.

Location on the sequence:   TCTTLIAHGNTESGLLTTHS  T WCTDSCQPITKTVEGTQVTM
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         T-CTTLIAHGNTESGLLTTHSTWCTDSCQPITKTVEGTQVTM

Mouse                         PFCITLVSHSGTDKGYLTTYSMWCTDTCQPIIKTVGGTQMT

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 21 – 151 Glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1
Domain 63 – 148 UPAR/Ly6
Region 103 – 109 Important for interaction with LPL
Disulfide bond 83 – 110
Mutagenesis 91 – 91 T -> A. Promotes formation of dimers and oligomers reducing number of monomers.
Mutagenesis 92 – 92 L -> A. Only slightly increased formation of dimers and oligomers. No effect on number of monomers. Loss of LPL interaction.
Mutagenesis 93 – 93 I -> A. Promotes formation of dimers and oligomers reducing number of monomers.
Mutagenesis 101 – 101 G -> S. Promotes formation of dimers and oligomers reducing number of monomers. Retained some interaction with LPL.
Mutagenesis 104 – 104 T -> A. Promotes formation of dimers and oligomers reducing number of monomers. Retained some interaction with LPL.
Mutagenesis 105 – 105 T -> A. Promotes formation of dimers and oligomers reducing number of monomers.
Mutagenesis 106 – 106 H -> L. Promotes formation of dimers and oligomers severely reducing number of monomers.
Mutagenesis 107 – 107 S -> A. Promotes formation of dimers and oligomers reducing number of monomers.
Mutagenesis 108 – 108 T -> A. Retained some interaction with LPL. No effect on number of monomers.
Mutagenesis 109 – 109 W -> CPT. Promotes formation of dimers and oligomers reducing number of monomers. Loss of LPL interaction.
Mutagenesis 109 – 109 W -> SYHAF. Loss of interaction with LPL. Only slightly increased formation of dimers and oligomers. No effect on number of monomers.
Mutagenesis 115 – 115 Q -> K. No effect on number of monomers.
Mutagenesis 126 – 126 V -> A. Promotes formation of dimers and oligomers reducing number of monomers.
Beta strand 99 – 113


Literature citations

Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia.
Surendran R.P.; Visser M.E.; Heemelaar S.; Wang J.; Peter J.; Defesche J.C.; Kuivenhoven J.A.; Hosseini M.; Peterfy M.; Kastelein J.J.; Johansen C.T.; Hegele R.A.; Stroes E.S.; Dallinga-Thie G.M.;
J. Intern. Med. 272:185-196(2012)
Cited for: VARIANTS HLPP1D TYR-65; ARG-108; PRO-115 AND PHE-144;

GPIHBP1 missense mutations often cause multimerization of GPIHBP1 and thereby prevent lipoprotein lipase binding.
Beigneux A.P.; Fong L.G.; Bensadoun A.; Davies B.S.; Oberer M.; Gaardsvoll H.; Ploug M.; Young S.G.;
Circ. Res. 116:624-632(2015)
Cited for: CHARACTERIZATION OF VARIANTS HLPP1D SER-65; TYR-65; ARG-68; GLY-68; TYR-68; PHE-89; ARG-108 AND PRO-115; SUBUNIT; INTERACTION WITH LPL; MUTAGENESIS OF TYR-66; LEU-71; THR-91; LEU-92; ILE-93; GLY-101; THR-104; THR-105; HIS-106; SER-107; THR-108; TRP-109; GLN-115 AND VAL-126;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.